ENDRA LIFE SCIENCES INC (NDRA)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
$6.05+6.51%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
QuarterlyIQ Insights · NDRA
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Complete the merger with Noble Africa and related transactions to create a Nasdaq-listed helium platform.
Stated as a priority in 3 disclosures including 2026-Q2 press release and two 2026-Q2 filings without fiscal period. Management announced the definitive merger agreement with Noble Africa, expected to close in Q4 2026, and a concurrent private placement expected to raise $50 million. The transaction is progressing as planned with closing anticipated in the fourth quarter, indicating delivering trajectory.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Entered into a definitive merger agreement with Noble Africa following strategic alternatives process.”
Strengthen balance sheet through private placements and consider share buybacks as part of capital allocation strategy.
Management stated this priority in 3 disclosures including 2026-Q2 and two filings without fiscal period. The company completed a $3.8 million private placement in May 2026 and announced share buyback plans in June 2026. Cash used in operations decreased to $0.9 million in 2026-Q2 from $1.1 million in 2025-Q2, reflecting disciplined capital management. The trajectory shows delivering progress in capital allocation.
“Completed a $3.8 million private placement strengthening the balance sheet.”
Implement workforce reductions and manage operating expenses to reduce cash burn and extend financial runway.
Stated in 2 disclosures including 2026-Q2 and a March 2026 press release. Management reduced workforce in March 2026 to lower cash expenditures and extend runway. R&D expenses fell 39% year-over-year in 2026-Q2, and cash used in operations declined from $1.1 million in 2025-Q2 to $0.9 million in 2026-Q2. The trajectory shows delivering progress in cost control and cash management.
“Research and development expenses decreased 39% compared with the second quarter of 2025.”
Over the trailing year it converted 0.83x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates (low R² over the window).
17 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.